Project Grant R01AR085008
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $313,358 to Cadenzamed LLC to develop a machine learning software tool for automatic segmentation and analysis of T1ρ MR images of knee cartilage. The goal is to create an imaging biomarker that can reliably measure osteoarthritis disease progression and responses to therapy in clinical...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $703,634 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Regents of the University of California, San Francisco (UCSF). The grant, awarded on August 15, 2025, will fund a study to develop and validate age-relative measures of biochemical intervertebral disc health. The research aims to discover the age-course of biochemical disc composition,...
- This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop computational tools to accurately predict and interpret different patterns of knee pain in patients with osteoarthritis. The $348,680 award, with a period of performance from Sep 26, 2024 to Aug 31, 2026, will enable researchers at the University of Arizona to: 1) Adapt a...
- The federal Project Grant award of $426,889.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the molecular regulatory mechanisms of a cartilage-enriched G-protein coupled receptor (GPCR) named ADGRG6 and its role in maintaining joint and cartilage homeostasis. The project, awarded to the University of Southern California, aims to investigate the...
- This Project Grant award, valued at $196,460.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The purpose of the award is to test a miniature knee joint system as a new tool to study the role of neuro-immune interactions in osteoarthritis pain. The University of Pittsburgh, the awardee, will use this novel microphysiological system with cartilage,...
- This $1,024,510 National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases project grant funds research at the University of California, San Francisco into simultaneous imaging of tissue biochemistry and metabolism associated with biomechanics in patellofemoral joint osteoarthritis. The research will conduct a longitudinal cohort study of 100 individuals with isolated patellofemoral joint osteoarthritis followed over two time points. Simultaneous positron...
- The University of Massachusetts Medical School was awarded a $1,066,302 project grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant will fund the creation of a biomedical knowledgebase to promote and facilitate the use of the Osteoarthritis Initiative (OAI), one of the most extensive osteoarthritis research cohorts. The knowledgebase will...
- This Project Grant award of $434,682 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The purpose of the award is to precisely define the proteolytic events and mechanisms along the timeline of post-traumatic osteoarthritis (PTOA), leveraging a specialized proteomics approach called "degradomics." The award recipient, the Cleveland Clinic...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to define the systemic mechanisms by which adipose (fat) tissue communicates with the knee joint to drive the development of osteoarthritis (OA). The $1,476,001 award to the Regents of the University of California, San Francisco will fund a comprehensive investigation of three potential interorgan crosstalk pathways: signaling through...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $412,610.00 to the Oklahoma Medical Research Foundation (OMRF) to investigate associations between the peripheral blood microbiome and knee osteoarthritis. The key objectives are to determine if baseline peripheral blood bacterial DNA patterns can predict future radiographic and...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), provides $675,131 in funding to the University of California, San Diego (UCSD) from August 1, 2025 to June 30, 2030. The goal of this project is to develop advanced magnetic resonance imaging (MRI) techniques, including ultrashort echo time (UTE) and adiabatic T1 mapping, to accurately diagnose and monitor early-stage osteoarthritis in the knee joint. This will involve mapping changes in proteoglycans and collagen across all major knee joint tissues, including short T2 tissues that are difficult to image using standard clinical MRI. The research aims to overcome key technical barriers in MRI imaging of early osteoarthritis, such as the magic angle effect and challenges with fat saturation, in order to create angular-independent biomarkers for clinical applications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $675.1k | 7/25/25 |